Member Info for equitrder

I think its consolidation..which is good, large spikes in share price usually need to be retraced... I think most ex-Fastnet shareholders are going to roll the dice for now.

Licence Agreement Terms Under the terms of our licence agreement, Amryt has the exclusive right to sell Lojuxta across its licenced territories in return for which Amryt will: · make royalty payments to Aegerion, paid quarterly, based on a percentage of net sales during a calendar year. The royalty percentage is 18% of net sales of the product less than US$15,000,000 and 20% of net sales more than US$15,000,000; · make once-off commercial milestone payments, subject to achieving certain sales targets. A one-off milestone payment of US$1,000,000 is due the first time that aggregate net sales in a calendar year equals US$20,000,000 with a further one-off US$1,500,000 milestone payment due on reaching US$30,000,000 net sales in a calendar year; and · take on the ongoing regulatory and post-marketing obligations and commitments in support of Lojuxta as above.

Revenues for the year to 31 December 2016 totalled €1,351,000 and comprised approximately one month's contribution from Lojuxta as well as well as a partial year's contribution from Imlan, the Company's derma-cosmetics range of products. The Lojuxta sales are for the period since the completion date on 2 December 2016 and totalled €775,000 in December. Very encouragingly, since the year end, Amryt recorded sales of €1,859,000 in January and February. Based on this, we expect Lojuxta to generate revenues of approximately €10.5 million on an annualised basis.

Radar..hopefully the plan is coming together..it's slow but there's definately progression. I remember at the original Fastnet equities shareholder meeting in the Doubletree Hilton they were talking about potential market cap of 500 mil.(I thought they were mad btw) One thing Cathal Friel said 'if we're around as an independent company in 2 years I'd be highly surprised'

Amryt Pharma shares soar as phase III trial for EB gets underway Share 09:11 28 Mar 2017 EB is a rare, genetic skin disorder, which causes exceptionally fragile skin picture of damaged skin EB affects 500,000 peole worldwide Amryt Pharma PLC (LON:AMYT) shares jumped 14% as it started a phase III trial for Episalvan, its treatment for rare skin condition Epidermolysis Bullosa (EB). EB is a rare, genetic skin disorder, which causes exceptionally fragile skin that blisters and tears at the slightest touch. There is currently no known cure for the condition. The disease can cause disfigurement and intense suffering especially among the young who are referred to as "Butterfly Children". Episalvan has already shown faster healing for wounds and chronic wounds compared to standard care. Amryt estimates that the global EB market is worth US$1.5bn per annum. The first site for the 'EASE' trial will be Sydney in Australia, with the the first patient to be randomised within the next few days. Amryt expects to conduct EASE in approximately 15 countries at over 30 sites and to enrol a total of 164 patients. Patients will be randomised in a double-blind fashion to AP101 (Episalvan) or placebo and the proportion of patients with completely healed target wounds within 45 days will be evaluated as the primary efficacy endpoint. Mark Sumeray, Amryt’s chief medical officer, said: “Our study, EASE, is of substantial size for such a rare disease and offers the opportunity to evaluate a new topical treatment with the potential to accelerate wound healing in this devastating disorder." Shares rose 1.86p to 21.9p.

.24

Breakeven for most of the initial large investors here is 24.

Well obviously Shore Capital don't have much of a following!!.......... 22k shares traded...

Is coming down rapidly

Yep I saw it...drop the bid right at the close

This stock has over 200 millions shares outstanding.We should be trading at least 500k shares a day.

I'm thinking Mr. Market is saying €8 billion market cap is what we are worth.

I mentioned back in January that Amryt might have a back door entry to Nasdaq... Here's my due diligence short and sweet ... Joe Wiley is on the board of directors on Innocoll Holdings based in Athlone...They had a refuse to file letter from the FDA late December for their drug Xaracoll (potentially a billion Dollar drug...now they are looking at strategic options to survive and are looking for an acquirer... If Xaracoll is good and Amryt could raise 20 to 30 mil there's a chance for a merger of equals and Nasdaq listing. Nothing concrete here just my mind ticking over..

Link is fine... Copy and paste

Just saw Richie walk by while having an early one in Mary Macs

Yep and volume is good on BIR for a so called quiet day.

Dont know what we can do...I contacted BOI Investor Relations and the said they don't comment on share price movements and to contact my broker..

You arrived

Nope I arrived on the scene mid 20's

You said single digits if memory serves me right so you were well off.